All In Biotech

Drug Trial Radar · NCT00171171

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Last checked: Nov 19, 2026Latest source record: Mar 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

252

Actual

Start

May 2004

Primary completion

Nov 2006

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Because patients with beta-thalassemia are unable to actively eliminate iron from the body, toxic and eventually lethal levels of iron can accumulate as a result of repeated blood transfusions. This study will evaluate the efficacy, safety and tolerability of deferasirox.

Conditions

  • Beta-Thalassemia
  • Hemosiderosis

Interventions

  • deferasiroxDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Liver Iron Concentration (as measured by biopsy)Time frame: at baseline and after 1 yeor of ICL670 treatment

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Cairo, Egypt

  • Ali Taher

    Beirut, Lebanon

  • Novartis Investigative Site

    Muscat, Oman

  • Novartis Investigative Site

    Riyadh, Saudi Arabia

  • Novartis Investigative Site

    Damascus, Syria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.